BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more
BioSenic S.A. (BIOS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.052x
Based on the latest financial reports, BioSenic S.A. (BIOS) has a cash flow conversion efficiency ratio of 0.052x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.39 Million) by net assets (€-26.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioSenic S.A. - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how BioSenic S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioSenic S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioSenic S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OPS Retail S.p.A.
F:DMM
|
N/A |
|
Odyssey Resources Limited
V:ODX-H
|
-0.155x |
|
USA Equities Corp
OTCQB:USAQ
|
-0.004x |
|
Atacama Resources International Inc
PINK:ACRL
|
0.010x |
|
Orian Sh.M. Ltd
TA:ORIN
|
0.016x |
|
NOVARTIS N - Dusseldorf Stock Exchang
DU:NOT
|
0.145x |
|
MeaTech 3D Ltd
PINK:MTTCF
|
-0.342x |
|
Blende Silver Corp.
OTCQB:BAGGF
|
-0.006x |
Annual Cash Flow Conversion Efficiency for BioSenic S.A. (2012–2024)
The table below shows the annual cash flow conversion efficiency of BioSenic S.A. from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-26.81 Million | €-2.23 Million | 0.083x | -45.50% |
| 2023-12-31 | €-22.70 Million | €-3.47 Million | 0.153x | +125.00% |
| 2022-12-31 | €3.12 Million | €-1.91 Million | -0.611x | -132.35% |
| 2021-12-31 | €-6.76 Million | €-12.78 Million | 1.890x | +139.07% |
| 2020-12-31 | €3.33 Million | €-16.08 Million | -4.837x | +4.75% |
| 2019-12-31 | €2.05 Million | €-10.40 Million | -5.078x | -76.78% |
| 2018-12-31 | €4.49 Million | €-12.90 Million | -2.873x | +37.87% |
| 2017-12-31 | €2.38 Million | €-11.02 Million | -4.624x | -521.01% |
| 2016-12-31 | €15.27 Million | €-11.37 Million | -0.745x | -78.12% |
| 2015-12-31 | €28.15 Million | €-11.77 Million | -0.418x | -212.50% |
| 2014-12-31 | €-9.48 Million | €-3.52 Million | 0.372x | +100.71% |
| 2013-12-31 | €63.00K | €-3.27 Million | -51.968x | -3284.99% |
| 2012-12-31 | €2.64 Million | €-4.05 Million | -1.535x | -- |